Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages E1830-E1837

  Alshayeb, Hala ^c   Showkat, Arif ^a   Wall, Barry M ^a,b   Gyamlani, Geeta G ^b   David, Valentin ^d   Quarles, L Darryl ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MARSHALL UNIVERSITY   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

24,25 DIHYDROXYVITAMIN D; CALCIUM; COLECALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHORUS; 25-HYDROXYVITAMIN D; FIBROBLAST GROWTH FACTOR; SECALCIFEROL; VITAMIN; VITAMIN D;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CHRONIC KIDNEY DISEASE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; END STAGE RENAL DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; SIGNAL TRANSDUCTION; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM; WILCOXON SIGNED RANKS TEST; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC KIDNEY FAILURE; DRUG MONITORING; KIDNEY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES; URINE; VITAMIN D DEFICIENCY;

24,25-DIHYDROXYVITAMIN D 3; AGED; CHOLECALCIFEROL; DRUG MONITORING; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARATHYROID HORMONE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84907611809     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1308     Document Type: Article

References (38)

1. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutrition. 2005;135:317-322.
2. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998;351:805-806.
3. 3 production. Am J Physiol. 1990;258:E780-E789.
4. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clinic proceedings. Mayo Clinic. 2006;81:353-373.
5. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31-38.
6. Rosen CJ, Abrams SA, Aloia JF, et al. IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrin Metab. 2012;97:1146-1152.
7. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrin Metab. 2011;96:1911-1930.
8. Heaney RP, Holick MF. Why the IOM recommendations for vitamin D are deficient. J Bone Miner Res. 2011;26:455-457.
9. National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-S201.
10. Garcia-Lopes MG, Pillar R, Kamimura MA, et al. Cholecalciferol supplementation in chronic kidney disease: restoration of vitamin D status and impact on parathyroid hormone. Ann Nutr Metab. 2012;61:74-82.
11. Marckmann P, Agerskov H, Thineshkumar S, et al. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant. 2012;27:3523-3531.
12. Alvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2012;96:672-679.
13. Quarles LD. The bone and beyond: 'Dem bones' are made for more than walking. Nat Med. 2011;17:428-430.
14. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429-435.
15. 2D levels does not support FGF23-mediated catabolism of vitamin D metabolites. Kidney Int. 2012;82:1061-1070.
16. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 asa causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500-6505.
17. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001;60:2079-2086.
18. Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor in dependent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005;289:F1088-F1095.
19. Tomiyama K, Maeda R, Urakawa I, et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci USA. 2010;107:1666-1671.
20. 3-24-hydroxylase, a multicatalytic enzyme. Biochemistry. 1996;35:8465-8472.
21. 3-1 alphahydroxylase knockout mice. Kidney Int. 2004;65:531-539.
22. Perwad F, Portale AA. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol Cell Endocrinol. 2011;347:17-24.
23. 3. Biosci Biotech Biochem. 2011;75:208-213.
24. Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys. 2012;523:9-18.
25. Horst RL, Littledike ET, Gray RW, Napoli JL. Impaired 24, 25-dihydroxyvitamin D production in anephric human and pig. J Clin Invest. 1981;67:274-280.
26. Horst RL, Shepard RM, Jorgensen NA, De Luca HF. The determination of 24, 25-dihydroxyvitamin D and 25, 26-dihydroxyvitamin D in plasma from normal and nephrectomized man. J Lab Clin Med. 1979;93:277-285.
27. Alshayeb HM, Wall BM, Showkat A, Mangold T, Quarles LD. Chronic kidney disease and diabetes mellitus predict resistance to vitamin D replacement therapy. Am J Med Sci. 2013;345:314-320.
28. Lips P. Vitamin D physiology. Progr Biophys Mol Biol. 2006;92:4-8.
29. Khosla S. What do we tell our patients about calcium and vitamin D supplementation? J Clin Endocrin Metab. 2011;96:69-71.
30. Helvig CF, Cuerrier D, Hosfield CM, et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int. 2010;78:463-472.
31. Bosworth CR, Levin G, Robinson-Cohen C, et al. The serum 24, 25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int. 2012;82:693-700.
32. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Int Med. 2010;152:640-648.
33. Kandula P, Dobre M, Schold JD, Schreiber MJ, Jr., Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011;6:50-62.
34. Shapses SA, Manson JE. Vitamin D and prevention of cardiovascular disease and diabetes: why the evidence falls short. JAMA. 2011;305:2565-2566.
35. 3 supplementations and doses adapted to baseline serum 25 (OH) D on achieved 25 (OH) D levels in patients with a recent fracture: a prospective observational study. Eur J Endocrinol. 2013;169:597-604.
36. Gravesen E, Hofman-Bang J, Lewin E, Olgaard K. Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5. Scand J Clin Lab Invest. 2013;73:107-116.
37. Tepper S, Shahar DR, Geva D, Ish-Shalom S. Predictors of serum 25 (Oh) D increase following bimonthly supplementation with 100, 000IU vitamin D in healthy, men aged 25-65 years [published online December 12, 2013]. J Steroid Biochem Mol Biol. doi: 10.1016/j.jsbmb.2013.12.005.
38. 3 supplementation. J Clin Endocrinol Metab. 2013;98:973-979.